Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment (300mg or 200 mg/Day) for Ovarian Cancer Patients
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Niraparib (Primary)
- Indications Carcinoma; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms NIRAPK
- 19 Apr 2022 Planned End Date changed from 1 Mar 2024 to 5 May 2026.
- 19 Apr 2022 Planned primary completion date changed from 1 Mar 2024 to 5 May 2026.
- 19 Apr 2022 Status changed from not yet recruiting to recruiting.